OCS Oculis Holding AG
Price Chart
Executive Summary
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the stock is driven by pipeline catalysts: OCS-01 DME Phase 3 topline data in June 2026, Licaminlimab DED readout around year-end, and Privosegtor SPA agreement. Cash of $277.6M provides runway into 2H 2029, reducing near-term dilution risk.
Actionable Insight
The EPS miss is minor for a pre-revenue biotech. The key catalyst is OCS-01 DME Phase 3 data in June 2026 — a positive readout could drive significant upside. Monitor for DIAMOND topline results as the primary near-term event. Cash runway into 2H 2029 removes financing overhang.
Key Facts
- Q1 2026 EPS -$0.42 vs consensus -$0.41 (2.7% miss)
- No revenue reported; pre-revenue biotech
- Cash, cash equivalents and short-term investments of $277.6M as of March 31, 2026
- OCS-01 DIAMOND Phase 3 DME trials LPLV completed; topline data expected June 2026
- Licaminlimab PREDICT-1 Phase 3 DED trial in site recruitment; topline expected year-end 2026
- Privosegtor received FDA SPA agreement for PIONEER-1 registrational trial in optic neuritis
- Net loss CHF 28.9M ($36.8M) vs CHF 33.2M ($36.9M) in Q1 2025
- R&D expenses CHF 14.0M ($17.9M), down from CHF 14.8M ($16.4M) in Q1 2025
Financial Impact
EPS miss of 2.7% is modest; cash burn ~$36.8M/quarter provides 3+ year runway
Risk Factors
- OCS-01 Phase 3 DME trials may fail to meet endpoints
- Licaminlimab PREDICT-1 DED trial may not replicate prior genotype-driven efficacy
- Privosegtor PIONEER program may face regulatory or enrollment delays
- Dilution risk from at-the-market offering program (used in Q1 2026)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Press Release
| $10.98 awaiting T+5 | awaiting T+5 | — | $11.09 (+1.00%) |
|
Jun 9, 2026
4d ago
|
Press Release
| $10.74 awaiting T+5 | awaiting T+5 | — | $11.09 (+3.31%) |
|
May 29, 2026
14d ago
|
Press Release
| $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $11.09 (+51.16%) |
|
May 11, 2026
4w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.09 (−63.53%) |
|
May 11, 2026
4w ago
|
Press Release
| $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $11.09 (−63.53%) |
|
May 7, 2026
5w ago
|
Press Release
| $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $11.09 (−64.33%) |
|
May 5, 2026
5w ago
|
Press Release
| $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $11.09 (−60.04%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $28.61 $27.12 | ▼ −5.21% | ▼ −6.12% | $11.09 (−61.24%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $26.02 $24.60 | ▼ −5.46% | ▼ −3.42% | $11.09 (−57.38%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $27.72 $27.28 | ▼ −1.59% | ▼ −0.25% | $11.09 (−59.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access